Abbokinase

   
Google
 
Web NewDrugInformation.com

Abbokinase


Drug - Abbokinase
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Urokinase
Multiple ingredients are in alphabetical order.

Strength - 250,000 IU/VIAL
The potency of the active ingredient(s), Urokinase. May repeat for multiple part products.

Applicant - ABBOTT
The firm name holding legal responsibility for Abbokinase. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 021846
The FDA assigned number to Abbokinase. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Abbokinase. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Approved Prior to Jan 1, 1982
The date Abbokinase was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Abbokinase. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Abbokinase is in. Format is RX, OTC, DISCN.

Applicant Full Name - Abbott Laboratories Pharmaceutical Products Div
The full name of the firm holding legal responsibility for the new application of Abbokinase.

Abbokinase